Skip to content
Directory

Treatment, Medication & Supplement Directory

A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.

Directory explains “what it is.”Guides explain how owners can discuss, use, monitor, or prepare for a treatment option with veterinary guidance.
Filtered (11)
Filtered (11)
Filter

Filter

11 directory found

Type
See more See less
Species
See more See less
See more See less
See more See less
See more See less
See more See less
See more See less
See more See less
See more See less
See more See less
Product Family
See more See less
Regulatory Status
See more See less
Region / Availability
See more See less
Search
Apply(11) Reset
Show (11)
Cancel
Apply(11) Reset
11 entriesShowing 1–11
Veterinarian reviewing a molecular target concept and an unbranded oral medicine with a dog caregiverNamed profile Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted TherapyRepresentative category illustration – no product packaging is shown.
Palladia / Toceranib · Prescription Drug · Targeted Therapy · Palladia · Dogs · After Targeted Therapy · During Targeted Therapy

Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy

Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node…

Read more
Veterinarian reviewing a molecular target concept and an unbranded oral medicine with a dog caregiverNamed profile Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine LymphomaRepresentative category illustration – no product packaging is shown.
Laverdia / Verdinexor · Prescription Drug · Targeted Therapy · Laverdia · Dogs · After Targeted Therapy · During Targeted Therapy

Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma

Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the…

Read more
Veterinarian reviewing a molecular target concept and an unbranded oral medicine with a dog caregiverNamed profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.
Prescription Drug · Targeted Therapy · Masivet · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy

Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors

Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.

Read more
Veterinarian reviewing hydration and digestive symptom monitoring with a dog caregiverNamed profile Canalevia-CA1 (Crofelemer): Chemotherapy-Induced Diarrhoea SupportRepresentative category illustration – no product packaging is shown.
Prescription Drug · Supportive-care medicine · Canalevia-CA1 · Dogs · After Chemotherapy · During Chemotherapy · Published Study

Canalevia-CA1 (Crofelemer): Chemotherapy-Induced Diarrhoea Support

crofelemer delayed-release tablets is covered as prescription antisecretory gastrointestinal medicine; supportive care, not antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Read more
Veterinarian demonstrating safe handling of an unbranded oral oncology medicine with a dog caregiverNamed profile Mitotane in Canine Adrenal Disease and Adrenocortical TumoursRepresentative category illustration – no product packaging is shown.
Chemotherapy · Prescription Drug · Single-agent Chemotherapy · Adrenocorticolytic agents · Dogs · During Chemotherapy · New Diagnosis

Mitotane in Canine Adrenal Disease and Adrenocortical Tumours

mitotane (o,p′-DDD) is covered as adrenocorticolytic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Read more
Caregiver and veterinary professional reviewing symptom observations for a dogNamed profile H1 and H2 Blockade Around Mast-Cell Degranulation RiskRepresentative category illustration – no product packaging is shown.
Prescription Drug · Supportive-care medicine · Mast-cell mediator blockade · Dogs · During Targeted Therapy · Veterinary Clinical Use · Label-linked companion-medication context

H1 and H2 Blockade Around Mast-Cell Degranulation Risk

H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led…

Read more
Veterinary team and caregiver reviewing an oncology treatment calendar for a dogNamed profile Melphalan and Prednisone or Prednisolone for Canine Multiple MyelomaRepresentative category illustration – no product packaging is shown.
Chemotherapy · Prescription Drug · Melphalan-glucocorticoid myeloma protocols · Dogs · During Chemotherapy · Long-term Management · New Diagnosis

Melphalan and Prednisone or Prednisolone for Canine Multiple Myeloma

melphalan with prednisone or prednisolone is covered as oral alkylator-based protocol for canine multiple myeloma, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Read more